RedHill Biopharma's Opaganib Gains FDA Rare Pediatric Disease Status for Neuroblastoma

MT Newswires Live06-09

RedHill Biopharma (RDHL) said Tuesday the US Food and Drug Administration has granted rare pediatric disease designation to opaganib for neuroblastoma, in addition to its existing orphan drug designation.

The designation could qualify the drug for a priority review voucher and provide benefits such as faster review, fee waivers, tax credits and potential seven-year market exclusivity if approved, the company added.

RedHill said the neuroblastoma market could reach $3.5 billion by 2032 and noted preclinical data supporting opaganib's potential in neuroblastoma and other cancers, including triple-negative breast cancer.

Shares of the company were down more that 12% in premarket trading Tuesday.

Price: 0.90, Change: -0.12, Percent Change: -12.75

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642462236?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642462236","market":"us","top_or_hot":-1,"title":"RedHill Biopharma's Opaganib Gains FDA Rare Pediatric Disease Status for Neuroblastoma","media":"MT Newswires Live","content":"<html><body><p> RedHill Biopharma (RDHL) said Tuesday the US Food and Drug Administration has granted rare pediatric disease designation to opaganib for neuroblastoma, in addition to its existing orphan drug designation.</p><p>The designation could qualify the drug for a priority review voucher and provide benefits such as faster review, fee waivers, tax credits and potential seven-year market exclusivity if approved, the company added.</p><p>RedHill said the neuroblastoma market could reach $3.5 billion by 2032 and noted preclinical data supporting opaganib's potential in neuroblastoma and other cancers, including triple-negative breast cancer.</p><p>Shares of the company were down more that 12% in premarket trading Tuesday.</p><p>Price: 0.90, Change: -0.12, Percent Change: -12.75</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RedHill Biopharma's Opaganib Gains FDA Rare Pediatric Disease Status for Neuroblastoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRedHill Biopharma's Opaganib Gains FDA Rare Pediatric Disease Status for Neuroblastoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-09 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> RedHill Biopharma (RDHL) said Tuesday the US Food and Drug Administration has granted rare pediatric disease designation to opaganib for neuroblastoma, in addition to its existing orphan drug designation.</p><p>The designation could qualify the drug for a priority review voucher and provide benefits such as faster review, fee waivers, tax credits and potential seven-year market exclusivity if approved, the company added.</p><p>RedHill said the neuroblastoma market could reach $3.5 billion by 2032 and noted preclinical data supporting opaganib's potential in neuroblastoma and other cancers, including triple-negative breast cancer.</p><p>Shares of the company were down more that 12% in premarket trading Tuesday.</p><p>Price: 0.90, Change: -0.12, Percent Change: -12.75</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642462236","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642462236","pubTimestamp":1781005531,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"RedHill Biopharma  said Tuesday the US Food and Drug Administration has granted rare pediatric disease designation to opaganib for neuroblastoma, in addition to its existing orphan drug designation.The designation could qualify the drug for a priority review voucher and provide benefits such as faster review, fee waivers, tax credits and potential seven-year market exclusivity if approved, the company added.RedHill said the neuroblastoma market could reach $3.5 billion by 2032 and noted preclinical data supporting opaganib's potential in neuroblastoma and other cancers, including triple-negative breast cancer.Shares of the company were down more that 12% in premarket trading Tuesday.Price: 0.90, Change: -0.12, Percent Change: -12.75","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RDHL":"Redhill Biopharma Ltd","LABU":"三倍做多标普生物-Direxion","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"RedHill Biopharma的Opaganib获得FDA神经母细胞瘤罕见儿科疾病地位","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"RDHL":1},"content_text":"RedHill Biopharma (RDHL) said Tuesday the US Food and Drug Administration has granted rare pediatric disease designation to opaganib for neuroblastoma, in addition to its existing orphan drug designation.The designation could qualify the drug for a priority review voucher and provide benefits such as faster review, fee waivers, tax credits and potential seven-year market exclusivity if approved, the company added.RedHill said the neuroblastoma market could reach $3.5 billion by 2032 and noted preclinical data supporting opaganib's potential in neuroblastoma and other cancers, including triple-negative breast cancer.Shares of the company were down more that 12% in premarket trading Tuesday.Price: 0.90, Change: -0.12, Percent Change: -12.75","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642462236","isCrawlerRequest":true}